审查Health Sciences Acquisition Co. 2（NASDAQ：HSAQ）和NuVasive（NASDAQ：NUVA）

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ – Get Rating) and NuVasive (NASDAQ:NUVA – Get Rating) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of recent ratings for Health Sciences Acquisitions Co. 2 and NuVasive, as provided by MarketBeat.

NuVasive has a consensus price target of $50.77, suggesting a potential upside of 18.14%. Given NuVasive's higher probable upside, analysts clearly believe NuVasive is more favorable than Health Sciences Acquisitions Co. 2.

Volatility and Risk

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Institutional & Insider Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Comparatively, 0.5% of NuVasive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and NuVasive's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Health Sciences Acquisitions Co. 2 and NuVasive's revenue, earnings per share (EPS) and valuation.

NuVasive has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Summary

NuVasive beats Health Sciences Acquisitions Co. 2 on 8 of the 10 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

(Get Rating)

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About NuVasive

(Get Rating)

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Receive News & Ratings for Health Sciences Acquisitions Co. 2 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Sciences Acquisitions Co. 2 and related companies with MarketBeat.com's FREE daily email newsletter.